Clinical Trial Oversight

Two deaths, one pathway: gene therapy's risk story is about oversight, not the edit

Both fatalities disclosed so far came out of China's investigator-initiated trial route, the lightest-touch pathway in the field. US lawmakers were pushing to copy parts of it in June.